Chemed Co. (NYSE:CHE) VP Michael D. Witzeman sold 2,174 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $430.00, for a total value of $934,820.00. Following the completion of the transaction, the vice president now directly owns 5,175 shares in the company, valued at $2,225,250. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of NYSE CHE opened at $436.18 on Thursday. The company has a quick ratio of 0.78, a current ratio of 0.81 and a debt-to-equity ratio of 0.25. The business’s 50 day moving average is $396.70 and its two-hundred day moving average is $345.80. The company has a market cap of $6.85 billion, a P/E ratio of 36.56, a P/E/G ratio of 2.93 and a beta of 1.14. Chemed Co. has a 12 month low of $260.03 and a 12 month high of $441.48.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, July 25th. The company reported $3.36 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.09 by $0.27. The company had revenue of $473.60 million for the quarter, compared to the consensus estimate of $471.72 million. Chemed had a return on equity of 35.63% and a net margin of 10.94%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.81 EPS. Sell-side analysts expect that Chemed Co. will post 13.54 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the company. Royal Bank of Canada raised their price objective on Chemed to $405.00 and gave the company a “sector perform” rating in a research note on Monday, July 29th. ValuEngine raised Chemed from a “hold” rating to a “buy” rating in a research note on Friday, June 7th. Oppenheimer raised their price objective on Chemed from $400.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research downgraded Chemed from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Chemed has an average rating of “Hold” and an average price target of $383.75.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cresset Asset Management LLC grew its holdings in shares of Chemed by 9.6% during the 2nd quarter. Cresset Asset Management LLC now owns 1,541 shares of the company’s stock worth $556,000 after purchasing an additional 135 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new stake in Chemed in the 2nd quarter valued at $236,000. Harvest Fund Management Co. Ltd boosted its stake in Chemed by 152.9% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 177 shares of the company’s stock valued at $64,000 after buying an additional 107 shares in the last quarter. Prudential PLC boosted its stake in Chemed by 27.3% in the 2nd quarter. Prudential PLC now owns 1,400 shares of the company’s stock valued at $505,000 after buying an additional 300 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in Chemed by 46.3% in the 2nd quarter. Royal Bank of Canada now owns 21,807 shares of the company’s stock valued at $7,868,000 after buying an additional 6,906 shares in the last quarter. 87.14% of the stock is currently owned by institutional investors.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.